Legal & General Group
TELO icon

Legal & General Group’s Telomir Pharmaceuticals TELO Stock Holding History

Legal & General Group’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,938
Closed -$6.27K – 3566
2025
Q1 		$6.27K Hold
1,938
– – ﹤0.01% 3248
2024
Q4 		$7.99K Buy
1,938
+1,188
+158% +$5.6K ﹤0.01% 3288
2024
Q3 		$4.79K Buy
+750
New +$3.66K ﹤0.01% 3371

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Legal & General Group's TELO Position: Q2 2025 in Review

Legal & General Group sold out of Telomir Pharmaceuticals (TELO) in Q2 2025, closing a stake of 1,938 shares — an estimated $6.27K sold.

Legal & General Group first reported a position in TELO in Q3 2024 and held it in 3 quarters. The position peaked at $7.99K in Q4 2024. 43 funds tracked by Wall St. Rank hold TELO as of Q2 2025.

  • Legal & General Group reported no remaining Telomir Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 1,938 Telomir Pharmaceuticals shares in Q2 2025, an estimated $6.27K.
  • Legal & General Group first reported a position in Telomir Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Legal & General Group's Telomir Pharmaceuticals position peaked at $7.99K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.